Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia James Shepherd, M.D., Stuart M. Cobbe, M.D., Ian Ford, Ph.D., Christopher.

Slides:



Advertisements
Similar presentations
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels Frank M. Sacks, M.D., Marc A. Pfeffer,
Advertisements

Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol VA-HIT Rubins, HB, et.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
Can we prevent stent restenosis after coronary stent implantation
Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.
Cholesterol and Lipids TIPS Wokefield Park 15/5/2013.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels Results of AFCAPS/TexCAPS John R. Downs, Michael.
Cholesterol quintile (mg/dL)
Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.
Department of Cardiology Government Medical college
TC LDL- C HDL- C Nonfatal MI/CHD death CHD death All- cause mortality *As compared to placebo. † P= CARE: Effect of Lipid Lowering on Lipid Values.
VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.
Cholesterol-Lowering Therapy in Women and Elderly Patients with Myocardial Infarction or Angina Pectoris Findings From the Scandinavian Simvastatin Survival.
Modern Management of Cholesterol in the High-Risk Patient.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.
Bezafibrate Infarction Prevention Trial (BIP) Results Presented at the European Society of Cardiology Meeting Vienna, Austria 1998.
Scandinavian Simvastatin Survival Study (4S) The Lancet, Vol 344, November 19, 1994.
HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,
Ten-Year Follow-up Survival of the Medicine, Angioplasty, or Surgery Study (MASS-II): a Randomized Controlled Clinical Trial of Therapeutic Strategies.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
OVERALL SURVIVAL Adapted from Scandinavian Simvastatin Survival Study Group Lancet 1994;344: % of patients alive Simvastatin (n=2221)
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Landmark clinical trials with pravastatin WOS CARE LIPID.
AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.
4S: Scandinavian Simvastatin Survival Study
Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Unnecessary Lipid Screening of Inpatient Admissions Dennis Whang 4/2/12 DSR2.
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease (HOPE-3 trial) R4. 박은지 / PF. 정혜문 Salim Yusuf, M.B., B.S., D.Phil.,
Presentation Title R3 이지영 / 김 수 중교 수 님. Introduction Lowering LDL cholesterol levels with statins : Reduce the risk of cardiovascular disease Vascular.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Title slide.
HOPE: Heart Outcomes Prevention Evaluation study
AIM HIGH Niacin plus Statin to prevent vascular events
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
First time a CETP inhibitor shows reduction of serious CV events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Scandinavian Simvastatin Survival Study (4S)
FATS- Familial Atherosclerosis Treatment Study
TNT: Baseline and final LDL cholesterol levels
Case 1: A 73-year-old white female with carotid disease
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.
LRC-CPPT and MRFIT Content Points:
Potential mechanisms whereby statins may reduce the risk of stroke
Cause of death Treatment-arm events, % (n=45 054)
Baseline Characteristics of the Subjects*
PROSPER: trial design                                                                                                                                                                 
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Presentation transcript:

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia James Shepherd, M.D., Stuart M. Cobbe, M.D., Ian Ford, Ph.D., Christopher G. Isles., M.D., A. Ross Lorimer, M.D., Peter W. Macfarlane, Ph. D., James H. McKillop, M.D., and Christopher J. Packard, D. Sc., for the West of Scotland Coronary Prevention Study Group N Engl J Med 1995;333:1301-7

Background This double-blind study was designed to determine whether the administration of pravastatin to men with hypercholesterolemia and no history of myocardial infarction reduced the combined incidence of nonfatal myocardial infarction and death from coronary heart diseaseThis double-blind study was designed to determine whether the administration of pravastatin to men with hypercholesterolemia and no history of myocardial infarction reduced the combined incidence of nonfatal myocardial infarction and death from coronary heart disease James Shepherd, et al, N Engl J Med 1995;333:1301-7

West of Scotland Coronary Prevention Study Group (WOS) Randomized, double-blind, placebo controlledRandomized, double-blind, placebo controlled 6595 men, 45 to 64 years of age6595 men, 45 to 64 years of age Average follow-up of 4.9 years (seen at 3 month intervals)Average follow-up of 4.9 years (seen at 3 month intervals) Pravastatin (40 mg each evening) vs. placeboPravastatin (40 mg each evening) vs. placebo James Shepherd, et al, N Engl J Med 1995;333:1301-7

WOS Baseline Characteristics Mean lipid levels:Mean lipid levels: –TC = 272 mg/dL –LDL = 192 mg/dL –HDL = 44 mg/dL –Trigs = mg/dL 5% of patients with angina5% of patients with angina 3% of patients with claudication3% of patients with claudication 8% of patients with abnormal EKG8% of patients with abnormal EKG 44% current smokers, 34% ex-smokers44% current smokers, 34% ex-smokers James Shepherd, et al, N Engl J Med 1995;333:1301-7

WOSCOPS: High Risk Primary Prevention Risk Factors... 1 risk factor:100 %1 risk factor:100 % 2 risk factors:44+ %2 risk factors:44+ % 3 risk factors:?3 risk factors:? Family history:?Family history:? Current CHD:5+ %?Current CHD:5+ %? James Shepherd, et al, N Engl J Med 1995;333:1301-7

Endpoints Primary Non-fatal MI or coronary heart disease death as a first event Non-fatal MI or coronary heart disease death as a first eventSecondary Non-fatal MINon-fatal MI Coronary heart disease deathCoronary heart disease death James Shepherd, et al, N Engl J Med 1995;333:1301-7

Other Endpoints Cardiovascular mortalityCardiovascular mortality Total mortalityTotal mortality Coronary revascularization proceduresCoronary revascularization procedures James Shepherd, et al, N Engl J Med 1995;333:1301-7

WOS Reduction in Lipids Pravastatin reduced lipid levels by*:Pravastatin reduced lipid levels by*: –20% reduction in TC –26% reduction in LDL –12% reduction in Trigs –5% increase in HDL *Data analyzed according to the treatment actually received not according to the intention-to-treat principle James Shepherd, et al, N Engl J Med 1995;333:1301-7

Effects of Pravastatin Therapy on Plasma LDL Cholesterol Levels James Shepherd, et al, N Engl J Med 1995;333: pravastatin (intention-to-treat) pravastatin (actual treatment) placebo (actual treatment) placebo (intention -to-treat)

Nonfatal MI or CHD Death (Primary Endpoint) 31%RiskReduction P= James Shepherd, et al, N Engl J Med 1995;333:1301-7

Non-Fatal MI (Secondary Endpoint) 31%RiskReduction P= James Shepherd, et al, N Engl J Med 1995;333:1301-7

CHD Death (Secondary Endpoint) 28% Risk Reduction P=0.13 James Shepherd, et al, N Engl J Med 1995;333:1301-7

Cardiovascular Death 32%RiskReduction P=0.033 James Shepherd, et al, N Engl J Med 1995;333:1301-7

Coronary Interventions Intervention PlaceboPravastatin Risk (n= 3293)(n=3302) Reductions p-value (n= 3293)(n=3302) Reductions p-valueCoronary Angiography % PTCA / CABG % James Shepherd, et al, N Engl J Med 1995;333:1301-7

Total Mortality P= %RiskReduction James Shepherd, et al, N Engl J Med 1995;333:1301-7

WOS Results/Clinical Events James Shepherd, et al, N Engl J Med 1995;333:1301-7

WOS Conclusions “Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of myocardial infarction.”“Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of myocardial infarction.” James Shepherd, et al, N Engl J Med 1995;333:1301-7

Projected Benefits Treatment of 1000 hypercholesterolemic middle aged men with pravastatin for five years will avoid: 14 coronary angiograms14 coronary angiograms 8 revascularization procedures8 revascularization procedures And avoid: 20 nonfatal MIs20 nonfatal MIs 7 CHD deaths7 CHD deaths 2 additional deaths2 additional deaths James Shepherd, et al, N Engl J Med 1995;333:1301-7